title: Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
abstract: Positron emission tomography (PET)/computed tomographic scanning, using 18F-2-deoxy-D-glucose, complements conventional imaging evaluation of patients with lung cancer. The strength of PET scanning lies in the detection of nodal and extrathoracic metastases. PET scanning is also currently being studied in the assessment of prognosis and therapeutic response and has the potential to alter management of oncologic patients. This review will discuss the role of PET/computed tomographic scanning in the diagnosis, staging, and evaluation of prognosis and treatment response in patients with lung cancer.
authors.affiliation: Division of Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. mtruong@mdanderson.org
authors.forename: Mylene T
authors.initials: MT
authors.lastname: Truong
authors.forename: Chitra
authors.initials: C
authors.lastname: Viswanathan
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Erasmus
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D003287:Contrast Media; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D051598:Whole Body Imaging
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18